Skip to main content
    G

    GRAIL, LLC (GRAL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $105.60
    -10.29 (-8.88%)

    Market Cap: $5.21B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    GRAIL, LLC (GRAL) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    GRAIL, LLC (GRAL) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, GRAIL, LLC reported EPS of -$2.21, above the -$2.78 estimate. It beat the EPS estimate in each of the last 9 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    100%(9/9)
    Avg Surprise
    +23.03%
    Streak
    9 Q

    Upcoming Estimates

    Reports Feb 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$2.20
    Range-$2.61 - -$1.44
    13 analysts
    Revenue Consensus
    $46.18M
    Range$42.71M - $49.35M
    12 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$2.49
    Range-$2.92 - -$1.73
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$2.89+13.8%
    60d ago-$2.89+13.8%
    30d ago-$2.87+13.2%
    7d ago-$2.87+13.2%
    Current-$2.49
    Revenue Consensus
    $45.78M
    Range$44.10M - $47.20M
    8 analysts

    Next Report

    GRAL has an expected report date of Feb 17, 2027.

    GRAL Earnings Call

    The latest GRAL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Revenue for the quarter ended Sep 30, 2026 was $37.53M, up 3.7% from $36.19M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$2.21-$2.78-$2.85 - -$1.49+20.50%BeatN/A41 up, 0 downNov 4, 2026$37.53M
    Jun 30, 2026-$2.56-$2.91-$2.97 - -$1.43+12.03%BeatN/A30 up, 1 downAug 5, 2026$44.69M
    Mar 31, 2026-$1.37-$1.96-$2.54 - -$1.44+30.10%BeatN/A42 up, 0 downMay 5, 2026$40.78M
    Dec 31, 2025-$2.44-$2.53-$2.87 - -$2.16+3.56%BeatN/A4N/AFeb 19, 2026$43.60M
    Sep 30, 2025-$2.46-$3.26-$3.48 - -$3.05+24.54%BeatN/A31 up, 0 downNov 12, 2025$36.19M
    Jun 30, 2025-$3.18-$3.56-$3.68 - -$3.36+10.67%BeatN/A3N/AAug 12, 2025$35.54M
    Mar 31, 2025-$3.10-$3.80-$3.80 - -$3.80+18.42%BeatN/A10 up, 0 downMay 13, 2025$31.84M
    Dec 31, 2024-$2.89-$4.97N/A+41.85%BeatN/AN/A0 up, 0 downFeb 20, 2025$38.25M
    Sep 30, 2024-$3.50-$6.43N/A+45.57%BeatN/AN/AN/ANov 12, 2024$28.65M
    Jun 30, 2024-$51.06N/AN/AN/AN/AN/AN/AN/AAug 13, 2024$31.97M
    Last 10 quarters

    Annual EPS

    Fiscal year endedEPSChange
    Sep 30, 2026-$6.14N/A
    Jun 30, 2026-$3.93N/A
    Dec 31, 2025-$11.18N/A
    Dec 31, 2024-$57.45N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,700 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,70313
    2026Q2Jun 30, 20265,80013
    2026Q1Mar 31, 20264,48013
    2025Q4Dec 31, 20256,16112
    2025Q3Sep 30, 20254,39810
    2025Q2Jun 30, 20254,71312
    2025Q1Mar 31, 20254,6789
    2024Q4Dec 31, 20243,0607

    2026Q3 Earnings Call

    Opening remarks

    GRAIL Investor Relations Investor Relations Thank you, and thank you all for joining us today. On the call are Josh Ofman, our Chief Executive Officer; Aaron Freidin, Chief Financial Officer; Sir Harpal Kumar, Chief Scientific Officer and President, Global Clinical and Medical Affairs; and Andy Partridge, Chief Growth Officer. I'll remind you that we'll be making forward-looking statements based on current expectations. It's our intent that all statements other than statements of historical facts, including statements regarding our anticipated financial results and commercial activity, will be covered by the safe harbor provisions for forward-looking statements under the federal securities laws. Forward-looking statements are subject to risks and uncertainties. Actual events or results may differ materially from those projected or discussed. All forward-looking statements are based upon currently available information, and GRAIL assumes no obligation to update these statements. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that GRAIL files with the Securities and Exchange Commission, including the Risk Factors section in GRAIL's most recent annual report on Form 10-K and the quarterly report on Form 10-Q we plan to file for the third quarter of 2026. This call will also include a discussion of GAAP results and certain non-GAAP financial measures, including adjusted gross profit, adjusted gross margin, and adjusted EBITDA, which exclude certain specified items. Our non-GAAP financial measures are intended to supplement your understanding of GRAIL's financials. Reconciliations of the non-GAAP measures to the most directly comparable GAAP financial measures are available in the press release issued today, which is available on our website. With that, we turn to Josh.

    Joshua Ofman CEO Thank you. Good afternoon, everyone, and thank you for joining us to review results for the third quarter of 2026 and to discuss recent business updates. GRAIL achieved multiple significant milestones this quarter, including a favorable vote for approval from the FDA's Advisory Committee and the publication of NHS-Galleri and PATHFINDER-2 results in the New England Journal of Medicine and Nature Medicine. These important clinical and regulatory milestones position us very well as we continue to progress toward future potential regulatory approval and reimbursement. As you know, we submitted our premarket approval application for Galleri to the FDA in January of this year. On September 23, the FDA convened an expert advisory committee to consider the safety, effectiveness, and overall benefit-risk profile of Galleri for screening for the early detection of multiple types of cancer in adults aged 50 years and older. Galleri is the first multi-cancer early detection test to undergo FDA review through the PMA pathway, and we were very pleased with the positive vote.

    Frequently Asked Questions About GRAL

    When is GRAIL, LLC's next earnings date?

    GRAIL, LLC's next earnings report is expected for Feb 17, 2027.

    Did GRAL beat earnings estimates last quarter?

    Yes. GRAIL, LLC reported EPS of -$2.21 for the quarter ended Sep 30, 2026, above the -$2.78 estimate, a 20.50% surprise.

    What EPS do analysts expect from GRAL next quarter?

    The consensus EPS estimate for GRAIL, LLC for the quarter ending Dec 31, 2026 is -$2.20 from 13 analysts, with estimates from -$2.61 to -$1.44.

    How often does GRAL beat earnings estimates?

    GRAIL, LLC beat the EPS estimate in each of the last 9 quarters, with an average surprise of +23.03%.